Suchergebnisse - "Hashizume, Misato"

PubPharm (74)

1

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma

enthalten in: Cancer science | 2021

von Terui, Y. | Rai, S. | Izutsu, K. | +18

2

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

enthalten in: Cancer Science | 2021

von Terui, Y. | Rai, S. | Izutsu, K. | +18

3

Outlook of IL-6 signaling blockade for COVID-19 pneumonia

enthalten in: Inflammation and regeneration | 2020

von Hashizume, M.

4

Outlook of IL-6 signaling blockade for COVID-19 pneumonia

enthalten in: Inflammation and regeneration | 2020

von Hashizume, M.

5

Translating IL-6 biology into effective treatments

enthalten in: Nature reviews. Rheumatology | 2020

von Choy, E. | De Benedetti, F. | Takeuchi, T. | +3

6

Outlook of IL-6 signaling blockade for COVID-19 pneumonia

enthalten in: Inflammation and regeneration | 2020

von Hashizume, M.

7

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

enthalten in: Journal of translational medicine | 2018

von O'Mahony, A. | John, M. | Cho, H. | +2

8

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

enthalten in: Journal of translational medicine | 2018

von O’Mahony, A. | John, M. | Cho, H. | +2

9

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

enthalten in: Journal of translational medicine | 2018

von O’Mahony, A. | John, M. | Cho, H. | +2

10

Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD

enthalten in: JCI insight | 2017

von Belle, L. | Zhou, V. | Stuhr, K. | +8

1
2
3
4
5
6
7
8
Nächster »
[8]